Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 53, No 2 (2019)
Review articles
Submitted: 2019-01-22
Accepted: 2019-01-22
Published online: 2019-03-11
View PDF Download PDF file
Get Citation

Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis

Krzysztof Barc1, Magdalena Kuźma-Kozakiewicz123
DOI: 10.5603/PJNNS.a2019.0013
·
Pubmed: 30855701
·
Neurol Neurochir Pol 2019;53(2):99-112.
Affiliations
  1. Department of Neurology, University Clinical Centre of Medical University of Warsaw, Warsaw, Poland
  2. Department of Neurology, Medical University of Warsaw, 8 Kondratowicza str, 03-242 Warsaw, Poland
  3. Neurodegenerative Disease Research Group, Medical University of Warsaw, Warsaw, Poland

open access

Vol 53, No 2 (2019)
Review articles
Submitted: 2019-01-22
Accepted: 2019-01-22
Published online: 2019-03-11

Abstract

Neurodegenerative diseases are a growing problem of ageing societies. Their insidious onset, and the lack of reliable biomarkers, result in significant diagnosis delays. This article summarises the results of studies on the use of positron emission tomography (PET) in the diagnosis of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. It focuses on clinical-pathogenetic aspects of individual diseases, as well as disease-specific patterns relevant in differential diagnosis and in assessing the risk of disease development and prognosis.

Abstract

Neurodegenerative diseases are a growing problem of ageing societies. Their insidious onset, and the lack of reliable biomarkers, result in significant diagnosis delays. This article summarises the results of studies on the use of positron emission tomography (PET) in the diagnosis of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. It focuses on clinical-pathogenetic aspects of individual diseases, as well as disease-specific patterns relevant in differential diagnosis and in assessing the risk of disease development and prognosis.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, positron emission tomography

About this article
Title

Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 53, No 2 (2019)

Pages

99-112

Published online

2019-03-11

Page views

2230

Article views/downloads

1701

DOI

10.5603/PJNNS.a2019.0013

Pubmed

30855701

Bibliographic record

Neurol Neurochir Pol 2019;53(2):99-112.

Keywords

Alzheimer’s disease
Parkinson’s disease
amyotrophic lateral sclerosis
positron emission tomography

Authors

Krzysztof Barc
Magdalena Kuźma-Kozakiewicz

References (148)
  1. Rabinovici GD. The translational journey of brain β-amyloid imaging: from positron emission tomography to autopsy to clinic. JAMA Neurol. 2015; 72(3): 265–266.
    CrossRefPubMed
  2. Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol. 2011; 38(1): 55–69.
    CrossRefPubMed
  3. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. Alzheimer's Disease International; London: 2015. World Alzheimer Report 2015. The Global Impact of Dementia. An analysis of prevalence, incidence, costs and trends. World Alzheimer's Report.
  4. Alexander GE, Chen K, Pietrini P, et al. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry. 2002; 159(5): 738–745.
    CrossRefPubMed
  5. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005; 32(4): 486–510.
    CrossRefPubMed
  6. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997; 42(1): 85–94.
    CrossRefPubMed
  7. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002; 17(1): 302–316.
    PubMed
  8. Kim EJ, Cho SS, Jeong Y, et al. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain. 2005; 128(Pt 8): 1790–1801.
    CrossRefPubMed
  9. Nestor PJ, Altomare D, Festari C, et al. EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018; 45(9): 1509–1525.
    CrossRefPubMed
  10. Whitwell J, Graff-Radford J, Tosakulwong N, et al. [18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology. 2018; 83(2): 248–257.
    CrossRef
  11. Tetzloff KA, Graff-Radford J, Martin PR, et al. Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. J Alzheimers Dis. 2018; 62(4): 1713–1724.
    CrossRefPubMed
  12. Patwardhan MB, McCrory DC, Matchar DB, et al. Alzheimer disease: operating characteristics of PET--a meta-analysis. Radiology. 2004; 231(1): 73–80.
    CrossRefPubMed
  13. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis. 2011; 26(4): 627–645.
    CrossRefPubMed
  14. Herholz K, Westwood S, Haense C, et al. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011; 52(8): 1218–1226.
    CrossRefPubMed
  15. Hsu JL, Hsu WC, Chang CC, et al. Everyday cognition scales are related to cognitive function in the early stage of probable Alzheimer's disease and FDG-PET findings. Sci Rep. 2017; 7(1): 1719.
    CrossRefPubMed
  16. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007; 68(20): 1718–1725.
    CrossRefPubMed
  17. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62(3): 229–234.
    CrossRefPubMed
  18. Chételat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin. 2013; 2: 356–365.
    CrossRefPubMed
  19. Spina S, Schonhaut DR, Boeve BF, et al. Frontotemporal dementia with the V337M mutation: Tau-PET and pathology correlations. Neurology. 2017; 88(8): 758–766.
    CrossRefPubMed
  20. Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016; 4(1): 58.
    CrossRefPubMed
  21. Tripathi M, Dhawan V, Peng S, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology. 2013; 55(4): 483–492.
    CrossRefPubMed
  22. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013; 79(6): 1094–1108.
    CrossRefPubMed
  23. Shinotoh H, Shimada H, Hirano S, et al. IMAGING OF TAU PATHOLOGY IN PATIENTS WITH NON-ALZHEIMER'S DISEASE TAUOPATHIES BY [11C]PBB3-PET. Alzheimer's & Dementia. 2014; 10(4): P6–P7.
    CrossRef
  24. Barrio JR, Small GW, Wong KP, et al. In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging. Proc Natl Acad Sci U S A. 2015; 112(16): E2039–E2047.
    CrossRefPubMed
  25. Barrio JR, Huang S-C, Cole G, et al. et al.. PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe. J Labelled Comp Radiopharm. 1999; 42: S194–S195.
  26. Agdeppa ED, Kepe V, Shoghi-Jadid K, et al. In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer’s disease patient: a case study. J Nucl Med. 2001; 42: 65P.
  27. Tauber C, Beaufils E, Hommet C, et al. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients. J Alzheimers Dis. 2013; 36(2): 311–320.
    CrossRefPubMed
  28. Barrio JR, Kepe V, Satyamurthy N, et al. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. J Nutr Health Aging. 2008; 12(1): 61S–65S.
    PubMed
  29. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006; 355(25): 2652–2663.
    CrossRefPubMed
  30. Giannakopoulos P, von Gunten A, Kövari E, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003; 60(9): 1495–1500.
    PubMed
  31. Gómez-Isla T, Price JL, McKeel DW, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996; 16(14): 4491–4500.
    PubMed
  32. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016; 79(1): 110–119.
    CrossRefPubMed
  33. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013; 34(2): 457–468.
    CrossRefPubMed
  34. Choi JY, Cho H, Ahn SJ, et al. Off-Target F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation. J Nucl Med. 2018; 59(1): 117–120.
    CrossRefPubMed
  35. Hansen AK, Knudsen K, Lillethorup TP, et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. Brain. 2016; 139(Pt 7): 2039–2049.
    CrossRefPubMed
  36. Lemoine L, Leuzy A, Chiotis K, et al. Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. Alzheimers Dement (Amst). 2018; 10: 232–236.
    CrossRefPubMed
  37. Harada R, Okamura N, Furumoto S, et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med. 2016; 57(2): 208–214.
    CrossRefPubMed
  38. Kang JM, Lee SY, Seo S, et al. Tau positron emission tomography using [F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. Neurobiol Aging. 2017; 59: 210–219.
    CrossRefPubMed
  39. Shimada H, Kitamura S, Shinotoh H, et al. Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [ 11 C]PBB3-PET study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2017; 6: 11–20.
    CrossRef
  40. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007; 64(3): 431–434.
    CrossRefPubMed
  41. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008; 131(Pt 6): 1630–1645.
    CrossRefPubMed
  42. Engler H, Nordberg A, Blomqvist G, et al. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol Aging. 2002; 23(1S): S429.
  43. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55(3): 306–319.
    CrossRefPubMed
  44. Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014; 137(Pt 6): 1762–1771.
    CrossRefPubMed
  45. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011; 68(11): 1398–1403.
    CrossRefPubMed
  46. Yeo JM, Waddell B, Khan Z, et al. A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. Alzheimers Dement (Amst). 2015; 1(1): 5–13.
    CrossRefPubMed
  47. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010; 68(3): 319–329.
    CrossRefPubMed
  48. Zwan MD, Bouwman FH, Konijnenberg E, et al. Diagnostic impact of [F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017; 9(1): 2.
    CrossRefPubMed
  49. Palmqvist S, Zetterberg H, Mattsson N, et al. Alzheimer's Disease Neuroimaging Initiative, Swedish BioFINDER Study Group. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015; 85(14): 1240–1249.
    CrossRefPubMed
  50. Tomita N, Furukawa K, Okamura N, et al. Brain accumulation of amyloid β protein visualized by positron emission tomography and BF-227 in Alzheimer's disease patients with or without diabetes mellitus. Geriatr Gerontol Int. 2013; 13(1): 215–221.
    CrossRefPubMed
  51. Rowe CC, Pejoska S, Mulligan RS, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med. 2013; 54(6): 880–886.
    CrossRefPubMed
  52. Mohandas E, Rajmohan V. Frontotemporal dementia: An updated overview. Indian J Psychiatry. 2009; 51 Suppl 1: S65–S69.
    PubMed
  53. Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med. 1998; 39(11): 1875–1878.
    PubMed
  54. Brown RKJ, Bohnen NI, Wong KaK, et al. Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics. 2014; 34(3): 684–701.
    CrossRefPubMed
  55. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008; 49(3): 390–398.
    CrossRefPubMed
  56. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007; 130(Pt 10): 2616–2635.
    CrossRefPubMed
  57. Kobylecki C, Langheinrich T, Hinz R, et al. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. J Nucl Med. 2015; 56(3): 386–391.
    CrossRefPubMed
  58. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011; 77(23): 2034–2042.
    CrossRefPubMed
  59. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009; 50(10): 1638–1645.
    CrossRefPubMed
  60. Dąbrowska M, Schinwelski M, Sitek EJ, et al. The role of neuroimaging in the diagnosis of the atypical parkinsonian syndromes in clinical practice. Neurol Neurochir Pol. 2015; 49(6): 421–431.
    CrossRefPubMed
  61. Villemagne VL, Okamura N, Pejoska S, et al. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. Neurodegener Dis. 2012; 10(1-4): 161–165.
    CrossRefPubMed
  62. Siderowf A, Pontecorvo MJ, Shill HA, et al. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC Neurol. 2014; 14: 79.
    CrossRefPubMed
  63. Johnson KA, et al. Combined dopamine transporter and FDG PET IN DLB, AD, and PD. Neurobiology of Aging. 2004; 25: S86–S87.
  64. Shimada H, Hirano S, Sinotoh H, et al. Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study. Int J Geriatr Psychiatry. 2015; 30(11): 1105–1113.
    CrossRefPubMed
  65. Kalaria R. Similarities between Alzheimer's disease and vascular dementia. Journal of the Neurological Sciences. 2002; 203-204: 29–34.
    CrossRef
  66. Nobili F, Arbizu J, Bouwman F, et al. EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018; 25(10): 1201–1217.
    CrossRefPubMed
  67. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003; 2(1): 15–21.
    PubMed
  68. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004; 63(12): 2332–2340.
    PubMed
  69. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005; 62(11): 1728–1733.
    CrossRefPubMed
  70. Morbelli S, Piccardo A, Villavecchia G, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging. 2010; 37(1): 36–45.
    CrossRefPubMed
  71. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995; 273(12): 942–947.
    PubMed
  72. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996; 334(12): 752–758.
    CrossRefPubMed
  73. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol. 2009; 30(2): 404–410.
    CrossRefPubMed
  74. Kemppainen NM, Scheinin NM, Koivunen J, et al. Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI. Eur J Nucl Med Mol Imaging. 2014; 41(2): 283–289.
    CrossRefPubMed
  75. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008; 29(10): 1456–1465.
    CrossRefPubMed
  76. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011; 76(12): 1085–1090.
    CrossRefPubMed
  77. Tolboom N, Yaqub M, van der Flier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med. 2009; 50(2): 191–197.
    CrossRefPubMed
  78. Grimmer T, Wutz C, Alexopoulos P, et al. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment. J Nucl Med. 2016; 57(2): 204–207.
    CrossRefPubMed
  79. Ng S, Villemagne VL, Berlangieri S, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med. 2007; 48(4): 547–552.
    PubMed
  80. Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013; 80(11): 1048–1056.
    CrossRefPubMed
  81. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009; 73(15): 1186–1192.
    CrossRefPubMed
  82. Stefanova E, Wall A, Almkvist O, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm (Vienna). 2006; 113(2): 205–218.
    CrossRefPubMed
  83. Tune L, Tiseo PJ, Ieni J, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry. 2003; 11(2): 169–177.
    PubMed
  84. Slawek J. Parkinson’s disease: how to properly diagnose and efectively and safely treat? (Article in Polish). Forum Medycyny Rodzinnej. 2014; 8(6): 281–291.
  85. Antony PMA, Diederich NJ, Krüger R, et al. The hallmarks of Parkinson's disease. FEBS J. 2013; 280(23): 5981–5993.
    CrossRefPubMed
  86. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology. 2013; 38(6): 938–949.
    CrossRefPubMed
  87. Bohnen NI, Müller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain. 2010; 133(Pt 6): 1747–1754.
    CrossRefPubMed
  88. Akdemir ÜÖ, Tokçaer AB, Karakuş A, et al. Brain 18F-FDG PET imaging in the differential diagnosis of parkinsonism. Clin Nucl Med. 2014; 39(3): e220–e226.
    CrossRefPubMed
  89. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005; 26(3): 912–921.
    CrossRefPubMed
  90. Wu P, Wang J, Peng S, et al. Metabolic brain network in the Chinese patients with Parkinson's disease based on 18F-FDG PET imaging. Parkinsonism Relat Disord. 2013; 19(6): 622–627.
    CrossRefPubMed
  91. Pal PK, Wszolek ZK, Uitti R, et al. Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes. Parkinsonism Relat Disord. 2001; 8(1): 51–56.
    PubMed
  92. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990; 28(4): 547–555.
    CrossRefPubMed
  93. Gao L, Chen H, Li X, et al. The diagnostic value of minor salivary gland biopsy in clinically diagnosed patients with Parkinson's disease: comparison with DAT PET scans. Neurol Sci. 2015; 36(9): 1575–1580.
    CrossRefPubMed
  94. Liu SY, Wu JJ, Zhao J, et al. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study. Parkinsonism Relat Disord. 2015; 21(12): 1448–1453.
    CrossRefPubMed
  95. Chung M, Park YS, Kim JiS, et al. Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET. Jpn J Radiol. 2015; 33(10): 609–618.
    CrossRefPubMed
  96. Hsiao IT, Weng YH, Hsieh CJ, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014; 71(6): 758–766.
    CrossRefPubMed
  97. Rinne JO, Laihinen A, Rinne UK, et al. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord. 1993; 8(2): 134–138.
    CrossRefPubMed
  98. Stark AJ, Smith CT, Petersen KJ, et al. [F]fallypride characterization of striatal and extrastriatal D receptors in Parkinson's disease. Neuroimage Clin. 2018; 18: 433–442.
    CrossRefPubMed
  99. Garcia-Garcia D, Clavero P, Gasca Salas C, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging. 2012; 39(11): 1767–1777.
    CrossRefPubMed
  100. Hosokai Y, Nishio Y, Hirayama K, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord. 2009; 24(6): 854–862.
    CrossRefPubMed
  101. Huang C, Mattis P, Perrine K, et al. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008; 70(16 Pt 2): 1470–1477.
    CrossRefPubMed
  102. Oh YS, Kim JS, Hwang EJ, et al. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson's disease. Parkinsonism Relat Disord. 2018; 56: 47–51.
    CrossRefPubMed
  103. Bohnen NI, Gedela S, Herath P, et al. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett. 2008; 447(1): 12–16.
    CrossRefPubMed
  104. Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002; 125(Pt 4): 861–870.
    PubMed
  105. Eggers C, Hilker R, Burghaus L, et al. High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease. J Neurol Sci. 2009; 276(1-2): 27–30.
    CrossRefPubMed
  106. Schreckenberger M, Hägele S, Siessmeier T, et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging. 2004; 31(8): 1128–1135.
    CrossRefPubMed
  107. la Fougère C, Pöpperl G, Levin J, et al. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med. 2010; 51(4): 581–587.
    CrossRefPubMed
  108. Zhao P, Zhang B, Gao S. 18[F]-FDG PET study on the Idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism & Related Disorders. 2012; 18: S60–S62.
    CrossRef
  109. Taniwaki T, Nakagawa M, Yamada T, et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J Neurol Sci. 2002; 200(1-2): 79–84.
    PubMed
  110. Bu LL, Liu FT, Jiang CF, et al. Patterns of dopamine transporter imaging in subtypes of multiple system atrophy. Acta Neurol Scand. 2018; 138(2): 170–176.
    CrossRefPubMed
  111. Kepe V, Bordelon Y, Boxer A, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis. 2013; 36(1): 145–153.
    CrossRefPubMed
  112. Passamonti L, Vázquez Rodríguez P, Hong YT, et al. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain. 2017; 140(3): 781–791.
    CrossRefPubMed
  113. Whitwell JL, Lowe VJ, Tosakulwong N, et al. [ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017; 32(1): 124–133.
    CrossRefPubMed
  114. Valli M, Strafella AP. New advances in tau imaging in parkinsonism. Int Rev Psychiatry. 2017; 29(6): 628–635.
    CrossRefPubMed
  115. Grijalvo-Perez AM, Litvan I. Corticobasal degeneration. Semin Neurol. 2014; 34(2): 160–173.
    CrossRefPubMed
  116. Niethammer M, Tang CC, Feigin A, et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain. 2014; 137(Pt 11): 3036–3046.
    CrossRefPubMed
  117. Laureys S, Salmon E, Garraux G, et al. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J Neurol. 1999; 246(12): 1151–1158.
    PubMed
  118. Smith R, Schöll M, Widner H, et al. In vivo retention of F-AV-1451 in corticobasal syndrome. Neurology. 2017; 89(8): 845–853.
    CrossRefPubMed
  119. Kikuchi A, Okamura N, Hasegawa T, et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology. 2016; 87(22): 2309–2316.
    CrossRefPubMed
  120. Hellwig S, Frings L, Amtage F, et al. 18F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism. J Nucl Med. 2015; 56(10): 1541–1546.
    CrossRefPubMed
  121. Hellwig S, Amtage F, Kreft A, et al. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012; 79(13): 1314–1322.
    CrossRefPubMed
  122. Fuente‐Fernández RD, Lu J, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology. 2001; 49(3): 298–303.
    CrossRef
  123. Chung SuJ, Lee Y, Oh JS, et al. Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off. Parkinsonism Relat Disord. 2018; 53: 96–100.
    CrossRefPubMed
  124. Fiszer U. The Current Status of Levodopa Treatment in Parkinson’s disease. (Article in Polish). Postępy Nauk Medycznych, t. Postępy Nauk Medycznych. 2012; XXV(1): 2012.
  125. Yoo HS, Chung SJ, Chung SuJ, et al. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease. Eur J Nucl Med Mol Imaging. 2018; 45(3): 423–431.
    CrossRefPubMed
  126. Whone AL, Watts RL, Stoessl AJ, et al. REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003; 54(1): 93–101.
    CrossRefPubMed
  127. Trost M, Su PC, Barnes A, et al. Evolving metabolic changes during the first postoperative year after subthalamotomy. J Neurosurg. 2003; 99(5): 872–878.
    CrossRefPubMed
  128. Sauleau P, Le Jeune F, Drapier S, et al. Weight gain following subthalamic nucleus deep brain stimulation: a PET study. Mov Disord. 2014; 29(14): 1781–1787.
    CrossRefPubMed
  129. Axelsen TM, Woldbye DPD. Gene Therapy for Parkinson's Disease, An Update. J Parkinsons Dis. 2018; 8(2): 195–215.
    CrossRefPubMed
  130. Yagi S, Yoshikawa E, Futatsubashi M, et al. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET. J Nucl Med. 2010; 51(8): 1250–1257.
    CrossRefPubMed
  131. Heller J, Brcina N, Dogan I, et al. Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) - A systematic review on potential biomarkers for neurodegeneration. Sleep Med Rev. 2017; 34: 23–33.
    CrossRefPubMed
  132. Holtbernd F, Gagnon JF, Postuma RB, et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology. 2014; 82(7): 620–627.
    CrossRefPubMed
  133. Arnaldi D, Morbelli S, Brugnolo A, et al. Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD. Parkinsonism Relat Disord. 2016; 29: 47–53.
    CrossRefPubMed
  134. Arnaldi D, De Carli F, Picco A, et al. Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder? Neurobiol Aging. 2015; 36(12): 3300–3305.
    CrossRefPubMed
  135. Saberi S, Stauffer JE, Schulte DJ, et al. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin. 2015; 33(4): 855–876.
    CrossRefPubMed
  136. Cistaro A, Valentini MC, Chiò A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012; 39(2): 251–259.
    CrossRefPubMed
  137. Pagani M, Chiò A, Valentini MC, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014; 83(12): 1067–1074.
    CrossRefPubMed
  138. Matías-Guiu JA, Pytel V, Cabrera-Martín MN, et al. Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging. 2016; 43(11): 2050–2060.
    CrossRefPubMed
  139. Lloyd CM, Richardson MP, Brooks DJ, et al. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain. 2000; 123 ( Pt 11): 2289–2296.
    PubMed
  140. Turner MR, Hammers A, Al-Chalabi A, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain. 2005; 128(Pt 6): 1323–1329.
    CrossRefPubMed
  141. Van Laere K, Vanhee A, Verschueren J, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014; 71(5): 553–561.
    CrossRefPubMed
  142. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004; 15(3): 601–609.
    CrossRefPubMed
  143. Zürcher NR, Loggia ML, Lawson R, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015; 7: 409–414.
    CrossRefPubMed
  144. Johansson A, Engler H, Blomquist G, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci. 2007; 255(1-2): 17–22.
    CrossRefPubMed
  145. Canosa A, Pagani M, Cistaro A, et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology. 2016; 86(1): 44–49.
    CrossRefPubMed
  146. Jeong Y, Park KC, Cho SS, et al. Pattern of glucose hypometabolism in frontotemporal dementia with motor neuron disease. Neurology. 2005; 64(4): 734–736.
    CrossRefPubMed
  147. Turner MR, Hammers A, Al-Chalabi A, et al. Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET. J Neurol. 2007; 254(8): 1033–1036.
    CrossRefPubMed
  148. Ikawa M, Okazawa H, Tsujikawa T, et al. Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology. 2015; 84(20): 2033–2039.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl